HARVARD BIOSCIENCE INC (HBIO): Nasdaq/NYSE listing notice — Harvard Bioscience receives Nasdaq bid-price deficiency; CFO Cote resigns effective May 12

HARVARD BIOSCIENCE INC

Nasdaq notified HBIO on April 4, 2025 of non-compliance with $1.00 minimum bid price; 180-day cure through Oct 1, 2025.
CFO Jennifer Cote resigns effective upon filing Q1 10-Q (due by May 12, 2025); resignation not due to any disagreement.
Mark Frost appointed interim CFO and Treasurer effective on Cote's departure; base salary $320k, $50k bonus tied to full debt repayment.
Frost receives 100k time-based RSUs vesting in one year, with pro-rata vesting if terminated without cause.
If not cured, HBIO may transfer to Nasdaq Capital Market for second 180-day period or face delisting.

item 3.01 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Mark Frost

Interim Chief Financial Officer and Treasurer

HBIO · HARVARD BIOSCIENCE INC

Filed: April 10, 2025, 7:59 PM ET

On April 10 2025, the Board of Directors of the Company appointed Mark Frost to serve as Interim Chief Financial Officer and Treasurer effective upon Ms. Cote’s resignation (the “Effective Date”).

Departed

Jennifer Cote

Chief Financial Officer and Treasurer

HBIO · HARVARD BIOSCIENCE INC

Successor: Mark Frost
Filed: April 10, 2025, 7:59 PM ET

On April 7, 2025, Jennifer Cote notified the Company of her resignation as Chief Financial Officer and Treasurer.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

HARVARD BIOSCIENCE INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

April 4, 2025, Harvard Bioscience, Inc. (the “Company”) received written notice (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1). Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the d

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Frost was appointed as Interim Chief Financial Officer and Treasurer at HARVARD BIOSCIENCE INC.

Action: appointed
Role: Interim Chief Financial Officer and Treasurer

Exact text from the filing

On April 10 2025, the Board of Directors of the Company appointed Mark Frost to serve as Interim Chief Financial Officer and Treasurer effective upon Ms. Cote’s resignation (the “Effective Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jennifer Cote resigned as Chief Financial Officer and Treasurer at HARVARD BIOSCIENCE INC.

Action: resigned
Role: Chief Financial Officer and Treasurer

Exact text from the filing

On April 7, 2025, Jennifer Cote notified the Company of her resignation as Chief Financial Officer and Treasurer.

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

HARVARD BIOSCIENCE INC filing history →

Source: SEC EDGAR

accession 0001171843-25-002149

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.